Clinical trial · Observational
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for HR+/HER2- Advanced/Metastatic Breast Cancer in Portugal
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospital drug consumption. The study included 16 public hospitals across Portugal, for which data on consumption of drugs used in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) a/mBC treatment was available. Patient selection was based on a set of criteria considering all patients with treatments in the a/mBC setting with use of at least one CDKI from November 2018 to May 2023.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Ribociclib Treatment Group
- description
- HR+/HER2- a/mBC patients with at least 1 month of ribociclib treatment.
- label
- Palbociclib Treatment Group
- description
- HR+/HER2- a/mBC patients with at least 1 month of palbociclib treatment.
- label
- Abemaciclib Treatment Group
- description
- HR+/HER2- a/mBC patients with at least 1 month of abemaciclib treatment.
Primary outcomes (4)
- measure
- Number of Patients Treated With a CDKI Between November 2018 and May 2023
- timeFrame
- Up to approximately 4 years and 6 months
- measure
- Median Treatment Duration
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: * Male and female patients of all ages. * Patients with at least one CDKI consumption from November 2018 to May 2023. * Patients with consumptions in Gynecology and Oncology specialties. Exclusion criteria: * Consumption patterns of target drugs that are not compatible with any known a/mBC treatment regimen. * Patients in early stages of breast cancer.
References
Publications (0)
Data not yet available